Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD Keros Therapeutics, Inc. Transaction History

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD

$1.17 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 01, 2022	SELL	$26.03 - $67.04 $2.49 Million - $6.41 Million	-95,644 Closed	0 $0
Q2 2021 Aug 04, 2021	BUY	$42.4 - $70.11 $4.06 Million - $6.71 Million	95,644 New	95,644 $4.06 Million

Others Institutions Holding KROS

# of Institutions

174

Shares Held

30.3M

Call Options Held

76.8K

Put Options Held

Black Rock Inc. New York, NY

2.51M
Shares

$45.2 Million
0.0% of portfolio
Alkeon Capital Management LLC New York, NY

1.9M
Shares

$34.2 Million
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

1.86M
Shares

$33.4 Million
0.0% of portfolio
Darwin Global Management, Ltd. St. Helier, Y9

1.52M
Shares

$27.4 Million
7.2% of portfolio
Price T Rowe Associates Inc Baltimore, MD

1.51M
Shares

$27.3 Million
0.01% of portfolio

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $464M
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD, based on Form 13F filings with the SEC.

News

Stay updated on Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD with notifications on news.

Account